# A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

> **NCT04138875** · PHASE2 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- PTLD
- Lymphoid Tumor
- Hematopoietic/Lymphoid Cancer
- Plasmacytic Hyperplasia PTLD
- Infectious Mononucleosis
- Florid Follicular Hyperplasia PTLD
- Polymorphic PTLD
- Monomorphic PTLD
- Classical Hodgkin Lymphoma Type PTLD

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Brentuximab Vedotin
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04138875
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01
- **Primary completion:** 2023-09
- **Final completion:** 2023-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138875, "A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04138875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*